Phaseline

Targets › STK11

STK11 (Serine/threonine-protein kinase STK11): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Tumor suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, thus promoting their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4,…. (UniProt, Q15831)

Open in Phaseline: the race on STK11, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Jiatan PharmatechWX390
STK11 inhibitor
STK11Phase 2Gastric Type Adenocarcinoma (GAS) With STK11 Mutation; Solid TumorDec 2026

Conditions

Gastric Type Adenocarcinoma (GAS) With STK11 Mutation (1) Solid Tumor (1)

Modalities

mixed (1)

Companies

Shanghai Jiatan Pharmatech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.